Last updated: 11/24/2025 05:51:24
Investigating otilimab in patients with severe pulmonary COVID-19 related diseaseOSCAR
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease
Trial description: OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related disease. The study is being conducted in 2 parts (Part 1 and Part 2). Otilimab is a human monoclonal anti-granulocyte macrophage colony stimulating factor (GM-CSF) antibody that has not previously been tested in participants with severe pulmonary COVID-19 related disease in Part 1. The aim of this study is to evaluate the benefit-risk of a single infusion of otilimab in the treatment of hospitalized participants with severe COVID-19 related pulmonary disease with new onset hypoxia requiring significant oxygen support or requiring early invasive mechanical ventilation (less than or equal to [<=] 48 hours before dosing). Participants will be randomized to receive a single intravenous (IV) infusion of otilimab or placebo, in addition to standard of care.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Parts 1 and 2: Proportion of participants alive and free of respiratory failure at Day 28
Timeframe: Day 28
Secondary outcomes:
Parts 1 and 2: Number of deaths due to all causes at Day 60
Timeframe: Day 60
Part 2: Number of deaths due to all causes at Day 28
Timeframe: Day 28
Parts 1 and 2: Time to number of deaths due to all causes up to Day 60
Timeframe: Up to Day 60
Parts 1 and 2: Proportion of participants alive and free of respiratory failure at Days 7, 14, 42 and 60
Timeframe: Days 7, 14, 42, and 60
Parts 1 and 2: Time to recovery from respiratory failure
Timeframe: Up to Day 28
Parts 1 and 2: Proportion of participants alive and independent of supplementary oxygen at Days 7, 14, 28, 42, and 60
Timeframe: Days 7, 14, 28, 42, and 60
Parts 1 and 2: Time to last dependence on supplementary oxygen
Timeframe: Up to Day 28
Part 1: Proportion of participants admitted to Intensive Care Unit (ICU)
Timeframe: Up to Day 28
Parts 1 and 2: Time to final ICU discharge
Timeframe: Up to Day 28
Part 1: Time to final hospital discharge
Timeframe: Up to Day 28
Part 2: Time to first discharge from investigator site
Timeframe: Up to day 60
Part 2: Time to first discharge to non-hospitalized residence
Timeframe: Up to day 60
Parts 1 and 2: Number of participants with Adverse events (AEs) and Serious adverse events (SAEs)
Timeframe: Up to Day 60
Interventions:
Enrollment:
1156
Primary completion date:
2021-15-07
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Patel J, Bass D, Beishuizen A, Bocca Ruiz X, Boughanmi H, Cahn T, Colombo H, Criner G, Davy K, de-Miguel-Díez J, Doreski P, Fernandes S, François B, Gupta A, Hanrott K, Hatlen T, Inman D, Isaacs J, Jarvis E, Kostina N, Kropotina T, Lacherade JC, Lakshminarayanan D, Martinez-Ayala P, McEvoy C, Meziani F, Monchi M, Mukherjee S, Muñoz-Bermúdez R, Neisen J, O'Shea C, Plantefeve G, Schifano L, Schwab L, Shahid Z, Shirano M, Smith J, Sprinz E, Summers C, Terzi N, Tidswell M, Trefilova Y, et al.. A Randomised Trial of Anti–GM-CSF Otilimab in Severe COVID-19 Pneumonia (OSCAR). Eur Respir J. 2023;61(2):2101870
DOI: 10.1183/13993003.01870-2021
PMID: 36229048
Medical condition
Severe Acute Respiratory Syndrome
Product
Otilimab
Collaborators
NA
Study date(s)
May 2020 to August 2021
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Inclusion criteria for Part 1:
- Participants aged >=18 years and <=79 years at the time of obtaining informed consent.
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria for Part 1:
- Participants aged >=18 years and <=79 years at the time of obtaining informed consent.
- Participants must: 1. have positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) result (any validated test, for example. reverse transcription polymerase chain reaction [RT-PCR] [performed on an appropriate specimen; for example: respiratory tract sample]) 2. and be hospitalized due to diagnosis of pneumonia (chest X-ray or computerized tomography [CT] scan consistent with COVID-19) 3. and be developing new onset of oxygenation impairment requiring any of the following: a. high-flow oxygen (>=15L/min) b. non-invasive ventilation (for example. CPAP, BIPAP) c. mechanical ventilation <=48 hours prior to dose 4. and have increased biological markers of systemic inflammation (either C-reactive protein [CRP] >upper limit of normal [ULN] or serum ferritin >ULN).
- No gender restriction.
- Female participants must meet and agree to abide by the contraceptive criteria detailed in the protocol. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- A female participant is eligible to participate if she is not pregnant or breastfeeding or if she is using highly effective contraceptive methods. Women of non-childbearing potential can also participate. A negative highly sensitive pregnancy test at hospital admission or before the first dose of study intervention.
- Capable of giving written informed consent. Inclusion Criteria for Part 2:
- Participants aged 70 years or above at the time of obtaining informed consent.
- Participants must: 1. have positive SARS-CoV-2 result (any validated test, for example. RT-PCR [performed on an appropriate specimen; for example. respiratory tract sample]) 2. and be hospitalized due to diagnosis of pneumonia (chest X-ray or CT scan consistent with COVID-19). 3. and be developing new onset of oxygenation impairment requiring any of the following: a. high-flow oxygen (>=15L/min) b. non-invasive ventilation (for example. CPAP, BiPAP) c. mechanical ventilation <=48 hours prior to dose 4. and have increased biological markers of systemic inflammation (either CRP >ULN or serum ferritin >ULN.
- No gender restriction.
- Capable of giving written informed consent. Exclusion Criteria for Part 1:
- Progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatments, in the opinion of the investigator.
- Multiple organ failure according to the investigator’s judgement or a Sequential Organ Failure assessment (SOFA score) >10 if in the ICU.
- Extracorporeal membrane oxygenation (ECMO) hemofiltration/dialysis or high-dose (>0.15 micrograms [mcg]/kilograms [kg]/min) noradrenaline (or equivalent) or more than one vasopressor.
- Current serious or uncontrolled medical condition (for example: significant pulmonary disease [such as severe chronic obstructive pulmonary disease (COPD) or pulmonary fibrosis], heart failure [New York Heart Association {NYHA} class III or higher], renal dysfunction, acute myocardial infarction or acute cerebrovascular accident within the last 3 months) or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.
- Untreated systemic bacterial, fungal, viral, or other infection (other than SARS-CoV-2).
- Known active tuberculosis (TB), history of untreated or incompletely treated active or latent TB, suspected or known extrapulmonary TB.
- Known Human Immunodeficiency Virus (HIV) regardless of immunological status.
- Known hepatitis B surface antigen (HBsAg) and/or anti-hepatitis C virus (HCV) positive.
- Currently receiving radiotherapy, chemotherapy or immunotherapy for malignancy.
- Received monoclonal antibody therapy (for examplee. tocilizumab, sarilumab) within the past 3 months prior to randomization, including intravenous immunoglobulin, or planned to be received, during the study.
- Received immunosuppressant therapy including but not limited to cyclosporin, azathioprine, tacrolimus, mycophenolate, Janus Kinase (JAK) inhibitors (for examplee. baricitinib, tofacitinib, upadacitinib) within the last 3 months prior to randomization or planned to be received during the study.
- History of allergic reaction, including anaphylaxis to any previous treatment with an anti-GM-CSF therapy.
- Received COVID-19 convalescent plasma within 48 hours of randomization.
- Currently receiving chronic oral corticosteroids for a non-COVID-19 related condition in a dose higher than prednisone 10 milligrams (mg) or equivalent per day.
- Treatment with an investigational drug within 30 days of randomization.
- Participating in other drug clinical trials, including for COVID-19.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times ULN.
- Platelets <50,000/cubic millimeters (mm^3)
- Hemoglobin <=9 grams per deciliter (g/dL)
- Absolute neutrophil count (ANC) <1.5 times 10^9/L (neutropenia >= Grade 2)
- Estimated glomerular filtration rate (GFR) <=30 milliliters (mL)/min/1.73 meter square (/m^2).
- Pregnant or breastfeeding females. Exclusion Criteria for Part 2:
- Progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatments, in the opinion of the investigator.
- Multiple organ failure according to the investigator’s judgement or a SOFA score >10 if intubated in the ICU.
- ECMO hemofiltration/dialysis, or more than one inotrope/vasopressor of any class.
- Current serious or uncontrolled medical condition (for example. significant pulmonary disease [such as severe COPD or pulmonary fibrosis], heart failure [NYHA class III or higher], severe renal dysfunction, acute myocardial infarction or acute cerebrovascular accident within the last 3 months), severe dementia, severe disability, or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.
- Untreated systemic bacterial, fungal, viral, or other infection (other than SARSCoV-2).
- Known active TB, history of untreated or incompletely treated active or latent TB, suspected or known extrapulmonary TB.
- Known HIV regardless of immunological status.
- Known HBsAg and/or anti-HCV positive (participants demonstrating a sustained virologic response (SVR) are not excluded from participation).
- Currently receiving radiotherapy, chemotherapy (hormone based therapies are permitted) or immunotherapy for malignancy.
- Received monoclonal antibody therapy (for example. tocilizumab, sarilumab) within the past 3 months prior to randomization, including intravenous immunoglobulin, or planned to be received during the study.
- Received immunosuppressant therapy including but not limited to cyclosporin, azathioprine, tacrolimus, mycophenolate, JAK inhibitors (for example. baricitinib, tofacitinib, upadacitinib), nintedanib, disease modifying antirheumatic drugs (DMARDs) (for example. methotrexate) within the last 3 months prior to randomization or planned to be received during the study.
- History of allergic reaction, including anaphylaxis to any previous treatment with an anti-GM-CSF therapy.
- Received COVID-19 convalescent plasma within 48 hours of randomization.
- Currently receiving chronic oral corticosteroids for a non-COVID-19 related condition at a dose higher than prednisone 10 mg or equivalent per day.
- Treatment with an investigational drug or substance within 30 days of randomization unless approved by the Medical Monitor.
- Participating in other drug clinical trials, including for COVID-19.
- AST or ALT >5 times ULN.
- Platelets <50,000/mm^3.
- Hemoglobin <=9 g/dL
- ANC <1.0 x 10^9/L (neutropenia >= Grade 3).
- Estimated GFR <=30 mL/min/1.73 m^2.
Trial location(s)
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28203
Status
Study Complete
Location
GSK Investigational Site
St. Paul, Minnesota, United States, 55101
Status
Study Complete
Location
GSK Investigational Site
St Louis Park, Minnesota, United States, 55426
Status
Study Complete
Location
GSK Investigational Site
Torrance, California, United States, 90502
Status
Study Complete
Location
GSK Investigational Site
San Sebastián de los Reyes/Madrid, Spain, 28702
Status
Study Complete
Location
GSK Investigational Site
L'Hospitalet de Llobregat, Spain, 08907
Status
Study Complete
Location
GSK Investigational Site
Silver Spring, Maryland, United States, 20910
Status
Study Complete
Location
GSK Investigational Site
Tacoma, Washington, United States, 98405
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140
Status
Study Complete
Location
GSK Investigational Site
Manchester, Greater Manchester, United Kingdom, M13 9WL
Status
Study Complete
Location
GSK Investigational Site
Germantown, Maryland, United States, 20876
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 01246-090
Status
Study Complete
Location
GSK Investigational Site
Winfield, Illinois, United States, 60190
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 01323903
Status
Study Complete
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V6Z 1Y6
Status
Study Complete
Location
GSK Investigational Site
Doylestown, Pennsylvania, United States, 18901
Status
Study Complete
Location
GSK Investigational Site
Roanoke, Virginia, United States, 24017
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 04037-003
Status
Study Complete
Location
GSK Investigational Site
Durban, KwaZulu- Natal, South Africa, 4052
Status
Study Complete
Location
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30130-100
Status
Study Complete
Location
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53295
Status
Study Complete
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
Status
Study Complete
Location
GSK Investigational Site
Jackson, Mississippi, United States, 39216
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21201
Status
Study Complete
Location
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
Status
Study Complete
Location
GSK Investigational Site
Newcastle, Northumberland, United Kingdom, NE2 4HH
Status
Study Complete
Location
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, C1039AAO
Status
Study Complete
Location
GSK Investigational Site
Sacramento, California, United States, 95819
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 05403-010
Status
Study Complete
Location
GSK Investigational Site
Gainesville, Florida, United States, 32608
Status
Study Complete
Location
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, 1842
Status
Study Complete
Location
GSK Investigational Site
Buffalo, New York, United States, 14215-1199
Status
Study Complete
Location
GSK Investigational Site
Mexico City, Ciudad de Mexico, Mexico, 14080
Status
Study Complete
Location
GSK Investigational Site
Johannesburg, Gauteng, South Africa, 2193
Status
Study Complete
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2021-15-07
Actual study completion date
2021-16-08
Plain language summaries
Summary of results in plain language
Available language(s): English (gsk-214094-plain-language-summary-part 1), English (gsk-214094-plain-language-summary-part 2), Bengali (gsk-214094-plain-language-summary-part 1-bnin), Bengali (gsk-214094-plain-language-summary-part 2-bnin), Dutch (Belgium) (gsk-214094-plain-language-summary-part 1-nlbe), Dutch (Belgium) (gsk-214094-plain-language-summary-part 2-nlbe.pdf
), Dutch (gsk-214094-plain-language-summary-part 1-nlnl), Dutch (gsk-214094-plain-language-summary-part 2-nlnl), French (Belgium) (gsk-214094-plain-language-summary-part 1-frbe), French (Belgium) (gsk-214094-plain-language-summary-part 2-frbe), French (Canadian) (gsk-214094-plain-language-summary-part 1-frca), French (Canadian) (gsk-214094-plain-language-summary-part 2-frca), French (gsk-214094-plain-language-summary-part 1-frfr), French (gsk-214094-plain-language-summary-part 2-frfr), Gujarati (gsk-214094-plain-language-summary-part 1-guin), Gujarati (gsk-214094-plain-language-summary-part 2-guin), Hindi (gsk-214094-plain-language-summary-part 1-hiin), Hindi (gsk-214094-plain-language-summary-part 2-hiin), Italian (gsk-214094-plain-language-summary-part 1-itit), Italian (gsk-214094-plain-language-summary-part 2-itit), Japanese (gsk-214094-plain-language-summary-part 1-jajp), Japanese (gsk-214094-plain-language-summary-part 2-jajp), Marathi (gsk-214094-plain-language-summary-part 1-mrin), Marathi (gsk-214094-plain-language-summary-part 2-mrin), Polish (gsk-214094-plain-language-summary-part 1-plpl), Polish (gsk-214094-plain-language-summary-part 2-plpl), Portuguese (Brazil) (gsk-214094-plain-language-summary-part 1-ptbr), Portuguese (Brazil) (gsk-214094-plain-language-summary-part 2-ptbr), Russian (gsk-214094-plain-language-summary-part 1-ruru), Russian (gsk-214094-plain-language-summary-part 2-ruru), Somali (gsk-214094-plain-language-summary-part 1-soso), Somali (gsk-214094-plain-language-summary-part 2-soso), Spanish (Argentina) (gsk-214094-plain-language-summary-part 1-esar), Spanish (Argentina) (gsk-214094-plain-language-summary-part 2-esar), Spanish (Chile) (gsk-214094-plain-language-summary-part 1-escl), Spanish (Chile) (gsk-214094-plain-language-summary-part 2-escl), Spanish (Columbia) (gsk-214094-plain-language-summary-part 1-esco), Spanish (Columbia) (gsk-214094-plain-language-summary-part 2-esco), Spanish (Mexico) (gsk-214094-plain-language-summary-part 1-esmx), Spanish (Mexico) (gsk-214094-plain-language-summary-part 2-esmx), Spanish (Peru) (gsk-214094-plain-language-summary-part 1-espe), Spanish (Peru) (gsk-214094-plain-language-summary-part 2-espe), Spanish (gsk-214094-plain-language-summary-part 1-eses), Spanish (gsk-214094-plain-language-summary-part 2-eses), Spanish (United States) (gsk-214094-plain-language-summary-part 1-esus), Spanish (United States) (gsk-214094-plain-language-summary-part 2-esus), Telugu (gsk-214094-plain-language-summary-part 1-tein), Telugu (gsk-214094-plain-language-summary-part 2-tein), Hmong (gsk-214094-plain-language-summary-part 1-hmnla), Hmong (gsk-214094-plain-language-summary-part 2-hmnla)
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website